Fortrea (FTRE) Q3 2026 earnings review
Fortrea lifts its sales outlook, but cuts backlog by $558M
Fortrea, which runs clinical trials for drugmakers, grew profit and cash flow while cleaning out old contracts from its backlog. Third-quarter sales dipped 1% from a year ago, but lower trial delivery costs more than doubled profit per share excluding one-offs and generated $53 million in free cash flow. Chief executive Anshul Thakral raised the middle of the full-year sales outlook, which by our math points to nearly 2% revenue growth in the fourth quarter.
| Revenue | $691.5M -1.4% from a year ago |
|---|---|
| Backlog, after $558M review cut | $7,316M -4.3% reported; +3.0% before cut |
| Profit per share, excluding one-offs | $0.28 $0.12 a year ago |
| Full-year revenue outlook | Raised $22.5M middle of the range: $2,678M (-1.7%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a $558 million backlog write-down offsets another quarter of solid bookings and cost control. Removing inactive trials and overestimated scope explains why five quarters of bookings above revenue had failed to lift total backlog, while the narrowed full-year profit plan still points to a fourth-quarter margin drop to 7.5% by our math.
The question now is whether the reset $7.3 billion backlog is finally clean enough to grow alongside bookings and turn into revenue growth in 2027. Optimists see five quarters of healthy bookings and a cleaner contract book; skeptics see a trimmed fourth-quarter profit ceiling and faster-burning early-stage work that may not rebuild the long-term book. Fourth-quarter backlog growth from this new base will tell.
🐂 Bull Case
Five Straight Quarters of Bookings Above Revenue
"Our sustained bookings momentum is building a foundation for growth," chief executive Anshul Thakral said. Fortrea measures demand with its book-to-bill ratio, which compares new contract awards against revenue recognized in the period. The ratio reached 1.12 in the third quarter, up from 1.06 in the second quarter, and kept the twelve-month ratio at 1.12.
By our math, a 1.12 ratio on $691.5 million of revenue means customers awarded Fortrea about $774 million of net new work, up from $720 million last quarter. Before the contract review, that flow would have lifted the backlog by $74 million from June. What to watch: whether the twelve-month ratio stays above 1.10 in the fourth quarter, which would support revenue growth in 2027.
Lower Trial Delivery Costs Lifted Operating Margin
Fortrea earned an operating profit for a second straight quarter even though revenue fell 1.4% from a year ago. Direct costs, the payroll and pass-through expenses of running clinical trials, fell 2.7 percentage points of revenue to 79.8%. Overhead and administrative costs also shrank by 0.2 percentage points to 15.0% of sales, while stock compensation dropped by nearly half.
Those savings lifted operating margin by 3.4 percentage points to 2.2% and raised profit per share, excluding one-offs, to $0.28 from $0.12 a year ago. What to watch: direct costs as a share of revenue in the fourth quarter. A reading below 80% would show that tighter project execution is holding.
Full-Year Outlook Points to Fourth-Quarter Revenue Growth
Revenue has declined from a year earlier for four consecutive quarters, though the drop narrowed from 4.5% in the second quarter to 1.4% in the third. Thakral raised the bottom of the full-year revenue outlook by $45 million, lifting the middle of the range to $2,677.5 million. By our math, that leaves $671.3 million for the fourth quarter.
Because the fourth quarter of 2025 was weak at $660.5 million, the new plan points to 1.6% growth from a year ago in the final quarter. That return to growth rests partly on an easy comparison, so one quarter will not settle the long-term trend. What to watch: whether fourth-quarter revenue clears the $679 million top of the implied range.
Positives this quarter didn't test
Fortrea said that targeted investments in early clinical development and technology "strengthen growth foundation", but the earnings release gave no numbers on three standing drivers.
- Early-stage clinical pharmacology trials: cited in the release without revenue or booking figures; the conference call will show whether fast-burning studies drove the 1.12 book-to-bill ratio.
- Fortrea Intelligent Technology (Fit, its artificial intelligence software for running trials): unmentioned in the release; the call will show if pilot programs are expanding.
- China biotechnology client sourcing: unmentioned in the release; management commentary on the call will show whether cross-border trial awards continued to grow.
🐻 Bear Case
Backlog Review Wipes Out $558 Million of Future Work
Backlog is the total value of contracted clinical trial work that Fortrea has not yet performed. The contract research group had reported a flat backlog near $7.8 billion for six quarters even though quarterly bookings consistently exceeded revenue. This quarter Fortrea audited its contracts and cut backlog by $558 million to "reflect the cumulative impact of estimated scope and study delivery requirements across customer contracts, including inactive trials."
- Reported backlog: $7,316 million, down 4.3% from a year ago and down $484 million from June
- Backlog before the review: $7,874 million by our math, up 3.0% from a year ago
- Third-quarter burn rate (revenue divided by opening backlog): 8.9% by our math, up from 8.6% in the second quarter
The company said the write-down does not affect its 2026 outlook or near-term revenue estimates. However, removing more than 7% of the book proves that older contracts carried dead weight and explains why past bookings failed to lift revenue. What to watch: whether fourth-quarter backlog grows from the reset $7,316 million base without further adjustments.
Full-Year Plan Still Points to a Fourth-Quarter Margin Drop
Fortrea raised the middle of its full-year Adjusted EBITDA outlook (earnings before interest, taxes, depreciation, amortization, and one-offs) by $1.5 million to $214 million, but it trimmed the top of the range from $220 million to $218 million. With $163.7 million already earned in the first nine months, the outlook leaves $50.3 million for the fourth quarter at the middle of the range.
By our math, that fourth-quarter figure represents a 6.9% drop from a year ago and an Adjusted EBITDA margin of 7.5%, down from 8.4% in the third quarter and 8.7% in the second. Cutting the top of the range after a strong third quarter shows that cost savings alone are not lifting late-year margins. What to watch: whether fourth-quarter Adjusted EBITDA beats the $54.3 million top of the implied range.
Risks this quarter didn't answer
Six standing concerns from prior quarters received no new figures in the third-quarter earnings release.
- Finance leadership and litigation: the release does not state whether the court injunction barring the incoming finance chief was resolved, though non-GAAP footnotes still list legal costs for the finance chief transition.
- Post-spinoff contract mix: management had targeted post-spinoff work to exceed 50% of full-service clinical development revenue in the second half of 2026, but the release gives no figure for a fifth straight quarter.
- Customer concentration: whether the top ten clients still account for over 55% of revenue will appear in the quarterly Form 10-Q filing.
- Cost savings progress: the release omits year-to-date gross and net cost savings against the $70–80 million gross and $40–50 million net full-year targets.
- Pass-through cost swings and artificial intelligence pricing pressure: neither pass-through revenue nor commentary on software-driven price compression appears in the release.
- High gross debt and twelve-month GAAP losses: gross debt stays above $1 billion and the twelve-month GAAP net loss is $68.7 million, leaving little cushion if trial demand slows.
💲 Other KPIs
Fortrea generated $52.5 million of free cash flow in the quarter, pushing nine-month free cash flow to $47.4 million and clearing its full-year target of positive cash generation. Cash on hand rose to $220.6 million, which lowered balance-sheet net debt to $834.7 million, or 3.8 times twelve-month Adjusted EBITDA by our math.
Unearned revenue — upfront payments from customers for clinical trial work not yet performed — rose to $525.5 million, up 27.7% from $411.6 million a year ago and up $22.8 million from June. Upfront cash collection has grown for four straight quarters even as reported revenue declined, supporting operating cash flow.
Diluted shares used to calculate profit per share excluding one-offs rose 7.9% from 93.8 million a year ago and increased from 99.4 million in the second quarter. Because the clinical research group does not repurchase stock, employee stock compensation continues to dilute existing shareholders each quarter.
🔮 Guidance
Raised. Fortrea lifted the bottom of its full-year sales plan by $45 million and kept the top unchanged, raising the middle of the range by $22.5 million to $2,677.5 million (-1.7% from 2025). By our math, that leaves $671.3 million for the fourth quarter (+1.6% from a year ago). Across four quarters, the middle of the range has moved by $0, +$55 million, and +$22.5 million.
Raised at the middle of the range. The US clinical research group lifted the floor by $5 million and trimmed the ceiling by $2 million, moving the middle up $1.5 million to $214 million (+12.7% from 2025). By our math, that leaves $50.3 million for the fourth quarter, down 6.9% from a year ago. Across four quarters, the middle of the range has moved by $0, +$7.5 million, and +$1.5 million.
❓ Key Questions
Were the $558 million of removed trials pre-spinoff contracts?
Fortrea cut its backlog by $558 million after reviewing contract scope and inactive trials. Investors need to know whether those removed studies came from the older pre-spinoff book or from recent biotechnology awards won over the past year.
Has post-spinoff work crossed 50% of full-service clinical revenue?
Management previously said that newer, higher-margin contracts won after the spinoff would exceed half of full-service clinical development revenue in the second half of 2026. The company has not disclosed that percentage for five quarters.
Why does the outlook imply a fourth-quarter margin drop?
By our math, the narrowed full-year Adjusted EBITDA plan leaves $46.3–54.3 million for the fourth quarter, or a 7.5% margin at the middle of the range versus 8.4% in the third quarter. Management has not explained what drives that step-down.
What is the status of the barred finance chief?
A court order in July prevented incoming finance chief Jason Nadblock from taking office, leaving a board director as interim finance chief. The release still shows legal costs for that dispute and gives no timeline for a permanent resolution.